Search research articles
Contact Us
Filters
Showing results (111-120 of 135) with videos related to
Page
of 14
Sort By:
Archives of Dermatological Research
|
September 11, 1999
Analysis of the tumor suppressor gene p16(INK4A) in microdissected melanoma metastases by sequencing, and microsatellite and methylation screening
F von Eggeling, G Werner, C Theuer, et al.
Annals of Hematology
|
March 23, 2004
Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial
G Heil, J Krauter, A Raghavachar, et al.
Leukemia & Lymphoma
|
February 1, 1997
Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation
W Krüger, M Stockschläder, I Sobottka, et al.
Otolaryngologia Polska = the Polish Otolaryngology
|
August 5, 2000
Clinical implications of telomerase activity and inactivation of the tumor suppressor gene p16 (CDKN2A) in head and neck cancer
S Koscielny, R Dahse, J Sonntag, et al.
Blood
|
June 22, 2001
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
R M Mesters, T Padró, R Bieker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer
E Laack, A Köhler, C Kugler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
E Briasoulis, N Pavlidis, C Terret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
C Theodore, L Geoffrois, J B Vermorken, et al.
Oncoimmunology
|
July 2, 2021
Increased frequency of TIGIT<sup>+</sup>CD73-CD8<sup>+</sup> T cells with a TOX<sup>+</sup> TCF-1low profile in patients with newly diagnosed and relapsed AML
F Brauneck, F Haag, R Woost, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 135) with videos related to
Sort By:
Page
of 14
Archives of Dermatological Research
|
September 11, 1999
Analysis of the tumor suppressor gene p16(INK4A) in microdissected melanoma metastases by sequencing, and microsatellite and methylation screening
F von Eggeling, G Werner, C Theuer, et al.
Annals of Hematology
|
March 23, 2004
Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial
G Heil, J Krauter, A Raghavachar, et al.
Leukemia & Lymphoma
|
February 1, 1997
Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation
W Krüger, M Stockschläder, I Sobottka, et al.
Otolaryngologia Polska = the Polish Otolaryngology
|
August 5, 2000
Clinical implications of telomerase activity and inactivation of the tumor suppressor gene p16 (CDKN2A) in head and neck cancer
S Koscielny, R Dahse, J Sonntag, et al.
Blood
|
June 22, 2001
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
R M Mesters, T Padró, R Bieker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer
E Laack, A Köhler, C Kugler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 15, 2003
Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group
E Briasoulis, N Pavlidis, C Terret, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 25, 2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers
C Theodore, L Geoffrois, J B Vermorken, et al.
Oncoimmunology
|
July 2, 2021
Increased frequency of TIGIT<sup>+</sup>CD73-CD8<sup>+</sup> T cells with a TOX<sup>+</sup> TCF-1low profile in patients with newly diagnosed and relapsed AML
F Brauneck, F Haag, R Woost, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Page
of 14